Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., ...More

BREAST, vol.22, no.5, pp.628-633, 2013 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1016/j.breast.2013.07.048
  • Journal Name: BREAST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.628-633
  • Keywords: HER2 positive, Lapatinib, Metastatic breast cancer, Vinorelbine, PLUS VINORELBINE, 1ST-LINE THERAPY, TRASTUZUMAB, SURVIVAL, GROWTH
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Background: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer.